Friday, December 2, 2022

INTERCEPT Blood System for Cryoprecipitation Receives FDA Approval States Cerus Corporation

November 30, 2020

INTERCEPT Blood System for Cryoprecipitation has received FDA approal reports Cerus Corporation. The system is used to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency.

After thawing, Pathogen Reduced Cryoprecipitated Fibrinogen Complex remains transfusion-ready at room temperature for up to 5 days, continuously available for administration over this extended period. This product has been granted an FDA Breakthrough Device designation based on the potential to improve the treatment of massive hemorrhage, a life-threatening medical condition.

“FDA approval of the INTERCEPT Blood System for Cryoprecipitation is an important step forward in our mission to establish pathogen reduction as the standard of care for transfused blood components globally,” said William ‘Obi’ Greenman, Cerus’ president and chief executive officer. “This is an important win for hospitals, clinicians and patients and also represents a new business model for Cerus. We plan to begin selling Pathogen Reduced Cryoprecipitated Fibrinogen Complex in California, Texas, Louisiana and Wisconsin in 2021, with expansion to national distribution in 2022 following anticipated approval of manufacturing site Biologics License Applications.”

In addition, to use for treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency, Pathogen Reduced Cryoprecipitated Fibrinogen Complex is also indicated for the control of bleeding when recombinant and/or specific virally inactivated preparations of factor XIII or von Willebrand factor are not available, for second-line therapy for von Willebrand disease, and for control of uremic bleeding after other treatment modalities have failed.

“Fibrinogen plays a critical role in controlling bleeding, but it has been difficult to provide quickly to massively bleeding patients. The extended room temperature shelf life, after thawing, of pathogen reduced cryoprecipitated fibrinogen complex allows it to be prepared in advance, which is essential because immediate availability will improve time to reversal of coagulopathy,” said Dr. Philip C. Spinella, Professor of Pediatrics and Director of the Critical Care Blood Research Program at Washington University in St. Louis. “I am optimistic that pathogen reduced cryoprecipitated fibrinogen complex will be a valuable tool to add to the tool box of therapies that are needed to support damage control resuscitation for patients with life threatening bleeding.”

In addition to the approval of Pathogen Reduced Cryoprecipitated Fibrinogen Complex, a derivative product from its production, called Pathogen Reduced Plasma, Cryoprecipitate Reduced, has also been approved by the FDA for transfusion or therapeutic plasma exchange in patients with thrombotic thrombocytopenic purpura (TTP).

For more information about the INTERCEPT Blood System for Cryoprecipitation, visit product website

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.
spot_img
spot_img

Our Sister Publication

Biotechnology News Magazine

By using this website you agree to accept Medical Device News Magazine Privacy Policy